Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.
Eur J Cancer. 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018. Epub 2021 Nov 19.
Eur J Cancer. 2022.
PMID: 34810048
Clinical Trial.
The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study.
Panhaleux M, Launay D, Penel N, Lambotte O, Forestier A.
Panhaleux M, et al.
Eur J Cancer. 2022 Apr;165:208-209. doi: 10.1016/j.ejca.2022.01.021. Epub 2022 Feb 27.
Eur J Cancer. 2022.
PMID: 35236567
No abstract available.
Item in Clipboard
Cite
Cite